Somdatta Lahiri, Pushkar Pushkar, Shibajyoti Ghosh


Background: The beneficial effects, if any, of adjuvant chemotherapy in terms of disease free survival (DFS) and quality of life (QOL) in patients of gall bladder carcinoma following radical cholecystectomy have not been adequately studied so far.

Objectives: We conducted this study to look into various parameters of QOL and DFS of gall bladder malignancy who received chemotherapy after radical cholecystectomy vis-à-vis the cases who did not receive perioperative chemotherapy.

Methodology: Total 30 cases were selected and divided into two groups – Group A (n=12 patients who underwent radical cholecystectomy alone) and Group B (n = 18 patients who received perioperative chemotherapy).  The patients were followed up for 18 months on various parameters of QOL and DFS according to the FACT HEP questionnaire.

Results: The mean age of our patients was 54 years and 76.71% were females. Most of the patients presented to us at stage III (46.7%) and stage II (36.7%).  The mean physical. functional, social and emotional wellbeing scores were better in the adjuvant chemotherapy group but the differences were not statistically significant. Statistically significant association (p value 0.0003) was found between survival and the stage at presentation.

Conclusion: QOL represented by physical, emotional, functional and additional concern parameters was generally in favour of chemotherapy group although statistically not significant. DFS was mostly dependent on stage at presentation.  The small sample size and nonrandomized study with short duration follow up and single institutional data were the major limitations of the study.


Gall bladder carcinoma, Radical cholecystectomy, Adjuvant chemotherapy, DFS, QOL, Chemotherapy.


Bottomley A, FleCTner H, and Efficace F, et al. (2005). “Health related quality of life outcomes in cancer clinical trials”, Eur J Cancer, Vol.41, pp.1697–1709.

Cihan S, Demicri NS, Odabas H, Ozdemir NY. (2015). “Adjuvant therapy in patients with gall bladder carcinoma”, Clinical Oncology, Elsevier Churchill Livingstone, Philadelphia, PA, p.1997.

De Aretxabala X, Roa I, Araya JC, Burgos L, Flores P, Wistuba I, Villaseca MA, Sotomayor F, and Roa JC. (1994). “Gallbladder cancer in patients less than 40 years old”, Br J Surg, Vol.81(1), p.111.

Dutta U, and Bush N. (2019). “Epidemiology of gallbladder cancer in India”, Chin Clin Oncol, Vol.8(4), p.33.

Hassan MAM, Wongjarupong N, and Sanhueza CT, et al. (2018). “Role of adjuvant therapy in gall bladder cancer”, Journal of clinical oncology, Vol.36(4), February, p.452, available online:

Hassanpour Dehkordi Ali, Heydarnejad MS, and Fatehi D. (2009). “Quality of Life in Cancer Patients undergoing Chemotherapy”, Oman medical journal, Vol.24, pp.204-207.

Horgan AM, Amir E, Walter T, Knox JJ. (2012). “Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and metaanalysis”, J Clin Oncol, Vol.30(16), pp.1934-1940.

Kasumova GG, Tabatabaie O, Miksad RA, Ng SC, Hidalgo MM, and Tsend JF. (2017). “Effect of adjuvant therapy on resected gallbladder adenocarcinoma: A propensity score matched analysis of national data”, Journal of clinical oncology, Vol.35(15), available online:

Lazcano-Ponce EC, Miquel JF, Muñoz N, Herrero R, Ferrecio C, Wistuba II, Alonso de Ruiz P, Aristi Urista G, and Nervi F. (2001) “Epidemiology and molecular pathology of gallbladder cancer”, CA Cancer J Clin, Vol.51(6), pp.349-364.

Nakayama F. (1991). “Recent progress in the diagnosis and treatment of carcinoma of the gallbladder – Introduction”, World J Surg, Vol.15(3), pp.313-314.

Pandey P, Pandey M, and Shukla VK. (2014). “Gall bladder cancers, survival and quality of life”, Int J Med Res Health Sci, Vol.3(3), pp.535-540.

Park HS, Lim JY, Yoon DS, Park JS, Lee DK, and Lee SJ, et al. (2010). “Outcome of adjuvant therapy for gallbladder cancer”, Oncology, Vol.79, pp.168-173.

Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, and Nakayama T, et al. (2002). “Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma”, Cancer, Vol.95(8), pp.1685-1695.

Velikova G, Awad N, and Coles-Gale R, et al. (2008). “The clinical value of quality of life assessment in oncology practice: a qualitative study of patient and physician views”, Psycho oncology, Vol.17, p.690.


  • There are currently no refbacks.

Send mail to with questions or comments about this web site. 

International Journal of Surgery and Surgical Sciences, All rights reserved.